Clinical significance of dysregulation of miR-381 in pediatric acute myeloid leukemia

Abstract

Background microRNA-381 is dysregulated in a variety of cancers. However, its clinical significance in pediatric acute myeloid leukemia (AML) is still unclear. The purpose of this study was to detect the expression level of miR-381 in pediatric AML patients and to explore its potential clinical significance. Methods The levels of miR-381 in bone marrow and serum of 102 pediatric AML patients were measured by quantitative real-time polymorperase chain reaction (qRT-PCR). The diagnostic value of serum miR-381 in pediatric AML patients was evaluated by the receiver operating characteristic (ROC) curve. A Chi square test was used to analyze the relationship between serum miR-381 and the clinical characteristics of patients. Cox regression analysis and Kaplan–Meier evaluated the prognostic value of serum miR-381 in patients. Finally, the proliferation of the cells was analyzed by the CCK-8 assay. Results Compared with healthy controls, the levels of miR-381 in serum and bone marrow of pediatric AML patients were significantly decreased (P < 0.001). ROC curve showed that miR-381 could distinguish pediatric AML cases from normal controls. At the same time, the downregulation of miR-381 was associated with M7 in the French–American–British (FAB) classifications and unfavorable cytogenetic risks (P < 0.05). Low serum miR-381 levels were associated with poor overall survival of pediatric AML (log-rank test, P = 0.011) and poor relapse-free survival (log-rank test, P = 0.004). Cox regression analysis confirmed that reduced serum miR-381 was an independent predictor of poor prognosis in AML (HR = 3.794, 95% CI 1.3633–10.559, P = 0.011). In addition, low expression of miR-381 significantly reduced the proliferation of cells (P < 0.05). Conclusion All experimental results confirm that miR-381 has reduced bone marrow and serum expression in pediatric AML, and low levels of serum miR-381 have certain diagnostic and prognostic value in pediatric AML and may be a potential therapeutic target for AML.

NEDD9 overexpression: Prognostic and guidance value in acute myeloid leukaemia

“…Downregulated microRNAs such as miR-135a, miR-203, miR-497, miR-381, miR-370 and miR-758 were found to be underexpressed in AML or have anti-leukaemia effects in previous reports. [29][30][31][32][33][34][35] Of these microRNAs, miR-381 was also identified as a microRNA that could direct target NEDD9 (Figure 5E and Table S2), which suggested NEDD9 is a direct target of miR-381.…”

Effective Prognostic Model for Therapy Response Prediction in Acute Myeloid Leukemia Patients

“…Acute myeloid leukemia (AML) is a clonal hematopoietic disorder characterized by the malignant transformation and abnormal proliferation of bone marrow-derived, self-renewing stem cells, or CD34+ CD38− myeloid progenitors [ 1 , 2 , 3 ]. AML is the most common acute leukemia in adults with an incidence of 2–4/100,000 per year and extremely short survival [ 4 ].…”